🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

RecruitingPhase 4Ages 18 Years - 80 YearsAllNabiqasim Industries (Pvt) Ltd
NCT06862739 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria 1. Patients of any gender 2. Patients aged between 18-80 years 3. Patients having HbA1c 8 % or above 4. Patients diagnosed with type II diabetes (more than at least 06 months) 5. Patients already on at least 02 or more anti-diabetic agents 6. Patients not allergic to empagliflozin, linagliptin, or metformin Exclusion criteria 1. Patients with age less than 18 2. Patients with Type-I diabetes 3. Patients having diabetes for less than 06 months 4. Patients on GLP-1 and GIP 5. Patients who are pregnant or lactating females 6. Patients with decompensated chronic liver disease (DCLD) 7. Patients with eGFR less than 30 ml 8. Patients with end-stage heart failure (NYHA Class 4) 9. Patients who are allergic to empagliflozin, linagliptin, or metformin 10. Patients who are not willing to consent 11. Patients who are unable to give medical history
💊

What it tests

  • Empagliflozin+Linagliptin+Metformin
📍

Where

2 sites
Faisalabad clinics
Faisalabad, Pakistan
Aap ka Clinic
Lahore, Pakistan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy